US 12,186,334 B2
High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions
Christopher Michael Kevin Springate, Richmond (CA); Ian Millet, Richmond (CA); Sailesh Haresh Daswani, Richmond (CA); and Hesong Sun, Richmond (CA)
Assigned to ARC Medical Inc., Richmond (CA)
Filed by ARC Medical Inc., Richmond (CA)
Filed on Jul. 27, 2022, as Appl. No. 17/874,382.
Application 17/874,382 is a continuation of application No. 17/260,272, granted, now 11,419,891, previously published as PCT/CA2019/051027, filed on Jul. 24, 2019.
Claims priority of provisional application 62/861,223, filed on Jun. 13, 2019.
Claims priority of provisional application 62/861,228, filed on Jun. 13, 2019.
Claims priority of provisional application 62/861,235, filed on Jun. 13, 2019.
Claims priority of provisional application 62/793,654, filed on Jan. 17, 2019.
Claims priority of provisional application 62/755,318, filed on Nov. 2, 2018.
Claims priority of provisional application 62/755,328, filed on Nov. 2, 2018.
Claims priority of provisional application 62/755,311, filed on Nov. 2, 2018.
Claims priority of provisional application 62/722,137, filed on Aug. 23, 2018.
Claims priority of provisional application 62/722,135, filed on Aug. 23, 2018.
Claims priority of provisional application 62/713,413, filed on Aug. 1, 2018.
Claims priority of provisional application 62/713,392, filed on Aug. 1, 2018.
Claims priority of provisional application 62/713,399, filed on Aug. 1, 2018.
Claims priority of provisional application 62/711,364, filed on Jul. 27, 2018.
Claims priority of provisional application 62/711,372, filed on Jul. 27, 2018.
Claims priority of provisional application 62/711,335, filed on Jul. 27, 2018.
Prior Publication US 2023/0140869 A1, May 11, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/737 (2006.01); A61P 41/00 (2006.01); C08B 37/00 (2006.01)
CPC A61K 31/737 (2013.01) [A61P 41/00 (2018.01); C08B 37/0003 (2013.01); C08B 37/0063 (2013.01)] 7 Claims
 
1. A high-molecular-weight fucan wherein the high-molecular-weight fucan consists of a molecular weight distribution wherein at least about 92% w/w of the molecular weight distribution of the fucan is greater than 100 kDa when measured using an aqueous gel permeation chromatography set up consisting of:
one 300 mm analytical gel permeation chromatography column with a 7.8 mm inner diameter packed with hydroxylated polymethacrylate-based gel, having an effective molecular weight range of between about 50 kDa and about 5,000 kDa, one 300 mm analytical gel permeation chromatography column with a 7.8 mm inner diameter packed with hydroxylated polymethacrylate-based gel, having an effective molecular weight range of between about 1 kDa and about 6,000 kDa and one 40 mm guard column with a 6 mm inner diameter packed with hydroxylated polymethacrylate-based gel, the two analytical gel permeation chromatography columns and the one guard column contained in a column compartment at about 30° C.;
a refractive index detector at about 30° C.;
0.1M sodium nitrate mobile phase run at 0.6 mL/min; and
quantification against a peak molecular weight standard curve consisting of a first dextran standard with a peak molecular weight of about 2,200 kDa, a second dextran standard with a peak molecular weight of between about 720 kDa and about 760 kDa, a third dextran standard with a peak molecular weight between about 470 kDa and about 510 kDa, a fourth dextran standard with a peak molecular weight between about 370 kDa and about 410 kDa, a fifth dextran standard with a peak molecular weight between about 180 kDa and about 220 kDa, and a sixth dextran standard with a peak molecular weight between about 40 kDa and 55 kDa.